News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Egetis to participate at upcoming medical conferences

August 30, 2022

Stockholm, Sweden, August 30, 2022. Egetis Therapeutics AB (publ) (Nasdaq Stockholm: EGTX) today announced that the Company will participate at the following upcoming medical conferences:
Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium
August 30 – September 2, 2022 in Freiburg, Germany

44th Annual Meeting of the European Thyroid Association (ETA)
September 10-13, 2022 in Brussels, Belgium

60th Annual Meeting of the European Society of Paediatric Endocrinology (ESPE)
September 15-17, 2022 in Rome, Italy

17th International Child Neurology Congress (ICNC)
October 3-7, 2022 in Antalya, Turkey

91st Annual Meeting of the American Thyroid Association (ATA)
October 19-23, 2022 in Montreal, Canada

Nicklas Westerholm, CEO, commented:As we are progressing towards our marketing applications for Emcitate for treatment of MCT8 deficiency in Europe and the US in 2023 it is important we further increase disease awareness of MCT8 deficiency among those doctors who might come across patients suffering from this rare and severe disease.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10